Long noncoding RNA ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 antisense RNA 1 recruits enhancer of zeste 2 polycomb repressive complex 2 subunit to promote the proliferation, migration and invasion of lung adenocarcinoma cells

Jinyuan Liu, Chunfeng Pan, Rongxin Lu, Shijiang ZhangBioengineered 2022 · DOI

TL;DR

This study reveals that a long noncoding RNA, ARAP1-AS1, acts as an oncogene in lung adenocarcinoma (LUAD) by recruiting the EZH2 protein. This interaction leads to the silencing of ARAP1, a tumor suppressor gene, thereby promoting cancer cell proliferation, migration, and invasion. The findings suggest ARAP1-AS1 as a potential therapeutic target for LUAD.

What Problem Does This Paper Address?

Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related death, often due to recurrence and metastasis. While long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, the specific functions and mechanisms of many lncRNAs in LUAD are not fully understood. ARAP1-AS1, a lncRNA antisense to the ARAP1 gene, has been implicated in other cancers, but its precise role in LUAD, particularly concerning cell migration and invasion, and its underlying molecular mechanisms, required further investigation. This paper aims to elucidate the function of ARAP1-AS1 in LUAD and identify its regulatory pathway.

Methods

The researchers employed a multi-pronged approach to investigate ARAP1-AS1's role in LUAD:

  • Gene Expression Analysis: RT-qPCR was used to measure ARAP1-AS1 and ARAP1 mRNA levels in LUAD cells and tissues, and bioinformatics databases (GEPIA, ENCORI) were used to analyze ARAP1-AS1 and EZH2 expression in patient cohorts.
  • Functional Assays: Standard cell biology techniques were used to assess the impact of ARAP1-AS1 manipulation on LUAD cell behavior:
  • MTT and Colony Formation Assays: To evaluate cell proliferation and viability.
  • Transwell Invasion Assay: To measure the ability of cells to invade through a matrix.
  • Wound Healing Assay: To assess cell migration.
  • Molecular Mechanism Studies:
    • Subcellular Fractionation: To determine the cellular localization of ARAP1-AS1.
  • Western Blotting: To analyze protein levels of ARAP1 and EZH2.
  • Luciferase Reporter Assay: To investigate the regulatory effect of ARAP1-AS1 and EZH2 on the ARAP1 promoter.
  • RNA Immunoprecipitation (RIP) Assay: To confirm the interaction between ARAP1-AS1, EZH2, and the ARAP1 promoter, specifically looking at H3K27me3 enrichment.
  • RNA Interference (RNAi): Specific shRNAs were used to knockdown ARAP1-AS1 and EZH2 expression in LUAD cells.

Datasets

The study utilized publicly available datasets for initial analysis:

  • GEPIA database: For analyzing ARAP1-AS1 and ARAP1 expression in normal and LUAD tissues.
  • ENCORI database: For analyzing EZH2 expression in normal and LUAD tissues.
  • Kaplan-Meier Plotter website: For predicting the correlation between ARAP1 expression and overall survival in LUAD patients.

In addition, the study used established human LUAD cell lines (A549 and H1975) and a normal human bronchial epithelial cell line (BEAS-2B) for experimental validation.

Key Insights and Ideas

  • ARAP1-AS1 as an Oncogene in LUAD: The study firmly establishes ARAP1-AS1 as a promoter of LUAD progression, driving proliferation, migration, and invasion. This is a significant finding, expanding its known oncogenic roles beyond other cancer types.
  • EZH2 as the Molecular Bridge: The critical insight is how ARAP1-AS1 exerts its effects: by recruiting EZH2. This highlights a specific mechanism of epigenetic regulation mediated by a lncRNA.
  • ARAP1 as a Tumor Suppressor Silenced by ARAP1-AS1/EZH2: The research identifies ARAP1 as a tumor suppressor gene that is epigenetically silenced by the ARAP1-AS1/EZH2 complex. This explains how ARAP1-AS1 promotes cancer by downregulating a gene that normally inhibits tumor growth.
  • Reversal of ARAP1-AS1 Effects by ARAP1 Restoration: Crucially, the study demonstrates that re-expressing ARAP1 can reverse the pro-cancerous effects induced by ARAP1-AS1 knockdown. This strongly implicates ARAP1 as the direct downstream target responsible for ARAP1-AS1's oncogenic activity.

Key Results

  • Upregulation of ARAP1-AS1: ARAP1-AS1 was found to be significantly upregulated in LUAD tissues and cell lines compared to normal counterparts.
  • ARAP1-AS1 Promotes Malignant Behaviors: Knockdown of ARAP1-AS1 significantly inhibited LUAD cell proliferation (MTT, colony formation assays), invasion (Transwell assay), and migration (wound healing assay). Conversely, ARAP1-AS1 overexpression enhanced these processes.
  • ARAP1 is Downregulated in LUAD: ARAP1 expression was found to be decreased in LUAD cells and tissues, and lower ARAP1 expression correlated with poorer patient survival.
  • ARAP1-AS1 Silences ARAP1 via EZH2: ARAP1-AS1 knockdown led to increased ARAP1 expression, and this effect was mediated by EZH2. ARAP1-AS1 was shown to recruit EZH2 to the ARAP1 promoter, leading to epigenetic silencing (indicated by H3K27me3 enrichment).
  • ARAP1 Restoration Rescues ARAP1-AS1 Knockdown Effects: Co-silencing ARAP1 along with ARAP1-AS1 abolished the inhibitory effects of ARAP1-AS1 knockdown on LUAD cell proliferation, migration, and invasion, confirming ARAP1's role as the key downstream effector.

Limitations and Future Work

The authors acknowledge two main limitations:

  • In Vitro vs. In Vivo Validation: The study's findings were primarily based on in vitro experiments. Further in vivo studies are needed to confirm ARAP1-AS1's oncogenic role in LUAD and its therapeutic potential.
  • Unexplored Signaling Pathways: While the study identified the ARAP1-AS1/EZH2/ARAP1 axis, other potential signaling pathways involved in LUAD tumorigenesis or progression that might be activated by ARAP1 regulation (e.g., TGF-β/Smad3 pathway, EGFR signaling) require further investigation.

The study suggests that ARAP1-AS1 could be a promising novel therapeutic target for LUAD, warranting further research into its clinical applicability.

Summary updated

Abstract

The detailed function of ARAP1-AS1, the antisense RNA of Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 (ARAP1), in lung adenocarcinoma (LUAD) has not been clearly elucidated and required further investigation. Our study is committed to exploring the role of ARAP1-AS1 in LUAD. Gene expression in LUAD was measured by real-time quantitative polymerase-chain reaction (RT-qPCR). The influence of ARAP1-AS1 on LUAD cell malignant behaviors was evaluated by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay, Transwell invasion assay and wound healing assay. Subcellular fractionation assay detected the cellular localization of ARAP1-AS1 in LUAD. The protein levels were subjected to western blotting. RNA immunoprecipitation (RIP) and luciferase reporter assay were employed to verify the interaction between ARAP1-AS1, ARAP1 and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2). Our investigation identified that ARAP1-AS1 was upregulated in LUAD cells and tissues. ARAP1-AS1 silencing repressed LUAD cell growth and migration. Furthermore, ARAP1-AS1 knockdown altered the expression of its sense mRNA, ARAP1. ARAP1-AS1 could recruit EZH2 to inhibit ARAP1 expression. Additionally, the downregulation of ARAP1 reversed ARAP1-AS1 downregulation-induced repression of cell growth and migration in LUAD. In conclusion, ARAP1-AS1 recruited EZH2 to silence ARAP1, facilitating cell proliferation, migration and invasion in LUAD. Our study demonstrated the possibility of ARAP1-AS1 to be a novel therapeutic target for LUAD. [Figure: see text].
BibTeX
@inproceedings{liu2022long,
  author = {Jinyuan Liu and Chunfeng Pan and Rongxin Lu and Shijiang Zhang},
  title = {{Long noncoding RNA ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 antisense RNA 1 recruits enhancer of zeste 2 polycomb repressive complex 2 subunit to promote the proliferation, migration and invasion of lung adenocarcinoma cells}},
  booktitle = {Bioengineered},
  year = {2022},
  doi = {10.1080/21655979.2022.2050968},
}
Figure